Summary of COVID-19 eritoran studies

1. Saito et al., Eritoran and Apremilast in hospitalized patients with COVID-19: the REMAP-CAP Immune Modulation-2 Domain

96 patient eritoran late treatment RCT: 26% higher mortality (p=0.69), 7% lower progression (p=1), and 1% improvement (p=0.99).
RCT 104 hospitalized patients with COVID-19 showing no significant difference in organ support-free days or mortality with eritoran (TLR4 antagonist) vs. placebo.
Sep 2026, CMI Communications, https://www.sciencedirect.com/science/article/pii/S2950590926000533, https://c19p.org/saito3